Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency... see more

TSX:MBX - Post Discussion

Microbix Biosystems Inc > pretty much as expected
View:
Post by RazeKreations on Nov 28, 2022 4:38pm

pretty much as expected

Today's investors update went pretty much as expected. Cameron was a little limited on how things are progressing because of fiscal year end report looming. They will be going into blackout period very shortly. Kinlytic opportunities are improving, that was one of the best little bits of information gained. They did explain why the update was so close to year end report and it was because of conflicts with travel and scheduling. He reported that there are 10 scientist working on developing new products. 100 employee's hired plus 10 contracted Lots of little bits of information on new opportunities and collaborations. Should have a better understanding of progress when fiscal year end report is posted. Then the webinar after that will bring much more insight into the company
Comment by rjc7 on Nov 28, 2022 4:46pm
Did they comment on how many shares have been repurchased. Thanks.
Comment by mercedesman on Nov 29, 2022 10:23am
Generally I agree, although I am bracing for a slightly slower uptick in new (QAP) order growth than originally might have been expected.  As Cameron mentioned, sales cycles can be long in Life Sciences. PCR testing (and therefore VTM need)  in ON currently at about 8000/day (250k/month).  They are "in discussions" to secure commitments for a large share of ON needs and ...more  
Comment by wizzdumb on Nov 29, 2022 10:48am
Cameron is a smart guy and would have learned his lesson on the Kinlytic guidance he provided near the end of last year which was very optimistic and even had a timeline associated with it, it ultimately did not come to pass. For him to basically inject some additional optimism into this in yesterdays call he's either quite certain about it or a glutton for punishment as he could have easily ...more  
Comment by mercedesman on Nov 29, 2022 11:31am
Wizz, I hope you are right that he is not a glutton for punishment. A more interesting question is what might their plans be for any cash raised from a possible sale ? Capacity expansion? - basically done. Share buy-back (to offset Option grants)? - already in the works at rate of 5%/year.  Current Cash flow can handle this easily Dividends?  - not in the ST cards per CG..and I agree ...more  
Comment by wizzdumb on Nov 29, 2022 11:51am
He did mention acquisitions a couple of times. He has his eye on something(s) I think. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities